AlphaCentric Advisors LLC Invests $691,000 in Edwards Lifesciences Co. (NYSE:EW)

AlphaCentric Advisors LLC bought a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 9,333 shares of the medical research company’s stock, valued at approximately $691,000.

Several other institutional investors also recently bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $30,000. FSA Wealth Management LLC acquired a new stake in Edwards Lifesciences in the 3rd quarter worth approximately $30,000. Prospera Private Wealth LLC purchased a new stake in Edwards Lifesciences during the 3rd quarter worth approximately $32,000. Avior Wealth Management LLC increased its stake in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares in the last quarter. Finally, Roble Belko & Company Inc acquired a new position in Edwards Lifesciences during the 4th quarter valued at approximately $46,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In other news, Director Steven R. Loranger sold 5,739 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now owns 60,372 shares of the company’s stock, valued at $4,613,628.24. This represents a 8.68 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the sale, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at $2,315,301.36. The trade was a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,489 shares of company stock worth $2,002,829 in the last ninety days. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Price Performance

EW stock opened at $76.23 on Monday. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The firm has a market capitalization of $44.96 billion, a PE ratio of 11.00, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The business has a 50 day simple moving average of $72.67 and a 200-day simple moving average of $69.54.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the topic of several research reports. Piper Sandler upped their target price on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Barclays increased their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday. Canaccord Genuity Group lifted their target price on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their price target for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Finally, Truist Financial restated a “hold” rating and set a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.